Corbus Pharmaceuticals Sets 2026 CRB-701 and CRB-913 Clinical Data Readouts
Corbus Pharmaceuticals plans data readouts for its pipeline candidates CRB-701 and CRB-913 throughout 2026. These clinical milestones represent key catalysts that could de-risk the drugs and drive share re-rating ahead of potential licensing or commercialization decisions.
1. Pipeline Overview
Corbus Pharmaceuticals is developing two lead assets, CRB-701 and CRB-913, targeting inflammatory and fibrotic disorders. CRB-701 is in mid-stage clinical testing and CRB-913 is completing early-phase safety and efficacy trials.
2. 2026 Data Readouts
The company has planned multiple clinical data readouts during 2026, including Phase II results for CRB-701 and interim Phase II data for CRB-913. These scheduled milestones are expected to provide proof-of-concept and inform future development decisions.
3. Valuation and Partnership Outlook
Positive clinical results could de-risk both assets, drive share re-rating and attract potential licensing or co-development partners. Detailed data will inform Corbus’s strategy for advancing its pipeline toward regulatory submissions and commercialization.